研究揭示了HER2和αVβ6 Integrin蛋白质如何在激进的乳腺癌中共同工作,导致抗药性。 Study reveals how HER2 and αVβ6 integrin proteins work together in aggressive breast cancer, leading to drug resistance.

研究人员确定了一种侵入性的HER2-阳性乳腺癌的机制,其中两种蛋白质,即HER2和αVβ6异狄氏剂,共同推动癌症细胞入侵和抗药性。 Researchers identified a mechanism in aggressive HER2-positive breast cancer where two proteins, HER2 and αVβ6 integrin, collaborate to drive cancer cell invasion and drug resistance. 这种相互作用在耐Tstruzumab的细胞中受到干扰,这是一种常见的治疗方法,可使人们深入了解治疗失败的情况。 This interaction is disrupted in cells resistant to trastuzumab, a common treatment, offering insights into treatment failure. 研究提出了预测治疗结果的潜在新治疗目标和生物标志。 The study suggests potential new therapeutic targets and biomarkers for predicting treatment outcomes.